RARX News

Six IPOs raised $2.3 billion this past week, including the year's largest US offering, China's logistics giant ZTO Express. ZTO priced above the range and proceeded to drop 15% on its first day, highly unusual given its pricing premium, size and origin. In fact, all four of this week's broken IPOs raised more proceeds than expected. The IPO market's one bright spot...read more

Ra Pharmaceuticals, which is developing small molecule therapies for rare immune disorders, raised $92 million by offering 7 million shares at $13, within the range of $12 to $14. Ra Pharmaceuticals plans to list on the Nasdaq under the symbol RARX. Credit Suisse, Jefferies and BMO Capital Markets acted as lead managers on the deal....read more

Six companies are on the US IPO calendar to raise $2.2 billion in the week ahead, or $2.6 billion including a large SPAC. October is set to surpass September as the year's most active month for IPOs. Filing activity has slowed heading into November, as expected.

• ...read more

Ra Pharmaceuticals, which is developing small molecule therapies targeting rare blood disorders, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5.8 million shares at a price range of $12 to $14. Insiders intend to purchase $30 million worth of shares in the offering. At the midpoint of the proposed range, Ra...read more